Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections

Next Previous
Trial Profile

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mavorixafor (Primary) ; Granulocyte colony-stimulating factors
  • Indications Neutropenia
  • Focus Registrational; Therapeutic Use
  • Acronyms 4WARD
  • Sponsors X4 Pharmaceuticals

Most Recent Events

  • 17 Sep 2025 According to a X4 Pharmaceuticals media release, the company announced a strategic restructuring designed to sharpen operational focus and align resources with the Company's long-term strategy to successfully complete the 4WARD Phase 3 trial in patients with moderate and severe chronic neutropenia.
  • 10 Jun 2025 According to a X4 Pharmaceuticals media release, potential top-line data from this study expected in late 2026.
  • 14 May 2025 According to a X4 Pharmaceuticals media release, based on Phase 2 trial results as supportive of the design of the Phase 3 trial and a signal of its potential for success.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top